

MESA LABORATORIES INC /CO  
Form 8-K  
March 02, 2015

---

---

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**February 27, 2015**

Date of Report (Date of earliest event reported)

**MESA LABORATORIES, INC.**

(Exact name of registrant as specified in its charter)

Commission File Number: **0-11740**

**COLORADO**

(State or other jurisdiction of  
incorporation)

**84-0872291**

(I.R.S. Employer  
Identification No.)

**12100 WEST SIXTH AVENUE,**

**LAKEWOOD, COLORADO**

(Address of principal executive offices)

**80228**

(Zip Code)

Registrant's telephone number, including area code: **(303) 987-8000**

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

---

---

**ITEM 8.01 OTHER EVENTS**

On February 27, 2015, Amilabo SAS (“Amilabo”), a wholly owned subsidiary of Mesa Laboratories, Inc. (the “Company”), entered into and closed an asset purchase agreement with Cherwell Laboratories Ltd. (“Cherwell”) whereby it acquired substantially all of the assets (other than cash and accounts receivable) and certain liabilities of Cherwell’s Biological Indicators distribution business.

On March 2, 2015, Amilabo entered into and closed an asset purchase agreement with Dr. Früh Control (“Früh”) whereby it acquired substantially all of the assets (other than cash and accounts receivable) and certain liabilities of Früh’s Biological Indicators distribution business.

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS**

(d)Exhibits:

99.1 Press release dated March 2, 2015.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DATE: March 2, 2015 Mesa Laboratories, Inc.  
( Registrant)

/s/ John J. Sullivan  
BY: John J. Sullivan,  
President and Chief Executive Officer